Loading stock data…
TERN
$52.93-0.02 (-0.04%)
Market ClosedLast close May 1
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Terns Pharmaceuticals, Inc. in the Healthcare sector is trading at $52.93. The stock is currently near its 52-week high of $53.19, remaining 92.3% above its 200-day moving average. Technical signals show overbought RSI of 79 and bearish MACD signal, explaining why TERN maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 79) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$52.93
Potential Upside
5%
Whystock Fair Value$55.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Hold
Mean target$53.00+0.1%
Range$53.00 – $53.00
Fundamentals
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.38
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.23%
Volume
Today's trading volume
2.75M
Recent News
Merck still sees ‘compelling’ outlook for Terns leukemia drug
Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
Merck Advances Terns Deal And Cardiovascular And RSV Growth Options
Merck (NYSE:MRK) reported the expiration of the Hart Scott Rodino waiting period for its pending acquisition of Terns Pharmaceuticals, clearing a key US regulatory hurdle. The Terns deal is intended to expand Merck’s presence in autoimmune and metabolic diseases. Merck announced CADENCE trial proof of concept data for Winrevair in heart failure with preserved ejection fraction. The European Commission approved ENFLONSIA for RSV prevention in infants. For investors following Merck, these...
UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview
Merck & Co., Inc. (NYSE:MRK) is included among the 10 Healthcare Stocks with Highest Dividends. On April 13, UBS analyst Michael Yee lifted the firm’s price recommendation on Merck & Co., Inc. (NYSE:MRK) to $145 from $130. It reiterated a Buy rating on the shares. The revision was part of a broader Q1 preview across […]
AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential?
Though both dominate oncology, a stronger growth outlook and clearer targets may give AstraZeneca an edge over Merck.
Why Terns Pharmaceuticals Stock Rocked the Market in March
A large peer is snapping up the company in a premium-priced deal.